Telitacicept, a novel bispecific fusion protein originally developed for systemic lupus erythematosus (SLE), simultaneously inhibits B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), two cytokines regulating B cell and plasma cell maturation. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.